IRD’s OPGX-BEST1 shows favorable Phase 1/2 safety, efficacy
OPGX-BEST1 showed favorable safety and clinically meaningful improvements in visual function and retinal structure in Phase 1/2 Cohort 1. FDA aligned on pivotal Phase 3 endpoints; Cohort 2 is over-enrolled as Phase 3 planning advances.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.